Low-grade astrocytoma (WHO grade 2) is a slow-growing, diffusely infiltrative glial tumor. Per WHO 2021 classification, it is defined as IDH-mutant astrocytoma. It typically occurs in young adults aged 20-40 with frontal or temporal lobe predilection. The most important imaging feature is absent or minimal contrast enhancement with homogeneous T2/FLAIR hyperintense signal. IDH mutation presence is associated with better prognosis, but there is risk of transformation to higher grade over time.
Age Range
20-50
Peak Age
35
Gender
Male predominant
Prevalence
Uncommon
Low-grade astrocytoma is a diffusely infiltrative glial tumor characterized by somatic mutation in the IDH1 or IDH2 gene. IDH mutation leads to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG); this metabolite can be detected as a specific peak at 2.25 ppm on MR spectroscopy. Tumor cells infiltrate individually within normal brain parenchyma but do not disrupt the blood-brain barrier — hence no contrast enhancement is observed. Due to low cellularity and slow proliferation, perfusion values (rCBV) are low and diffusion restriction is not prominent. T2/FLAIR hyperintensity reflects increased water content and myelin loss accompanying tumoral infiltration. Over time, accumulation of genetic alterations (such as CDKN2A/B homozygous deletion) may lead to transformation to higher grade.
An infiltrative lesion showing homogeneous hyperintense signal on T2/FLAIR but no enhancement on post-contrast sequences is the diagnostic key finding of low-grade astrocytoma. This combination reflects diffuse infiltrative tumor growth with intact blood-brain barrier and is the key distinguishing feature from high-grade gliomas (enhancement positive). This pattern in a young adult at frontal/temporal location strongly supports the diagnosis of low-grade glioma.
On non-contrast CT, an ill-defined, homogeneously hypodense mass is observed. Calcification is generally absent (unlike oligodendroglioma). Mass effect is minimal or absent. No or minimal enhancement on contrast-enhanced CT. CT has low sensitivity for detecting low-grade astrocytoma and many lesions may be missed — MRI is clearly superior. MRI is mandatory when a hypodense area is detected on CT in young patients presenting with acute seizure.
Report Sentence
An ill-defined, homogeneously hypodense area measuring approximately _x_x_ cm is identified in the right/left frontal/temporal lobe, without calcification or significant mass effect. MRI is recommended for further evaluation.
On T1-weighted sequences, a homogeneously hypointense mass lesion is observed. Hypointensity reflects increased water content from tumoral infiltration. Margins are generally ill-defined on T1 (diffuse infiltrative growth). On T1 post-contrast sequences, no enhancement is observed, or only faint punctate enhancement may be present. New or increasing enhancement suggests transformation to higher grade (malignant transformation) and is an indication for urgent biopsy. Hemorrhagic component is generally absent.
Report Sentence
On T1-weighted sequences, an ill-defined homogeneously hypointense area is observed, with no enhancement on post-contrast T1 sequences.
The most characteristic imaging finding of low-grade astrocytoma is observed on T2 and FLAIR sequences: homogeneous hyperintense signal change. Lesion margins are generally ill-defined with no sharp border between normal brain parenchyma and tumor — reflecting diffuse infiltrative growth pattern. Hyperintense signal is more conspicuous on FLAIR than T2, and lesion margins are better evaluated (due to CSF suppression). Cortical infiltration ('cortical thickening' or 'blurring') is best seen on FLAIR. Edema-tumor distinction is difficult because pure edema is minimal — the majority of hyperintense area represents tumoral infiltration. Development of heterogeneity or new cystic/necrotic areas suggests transformation to higher grade.
Report Sentence
On T2 and FLAIR sequences, ill-defined homogeneous hyperintense signal change is observed in the right/left frontal/temporal lobe with cortical infiltration. No contrast enhancement is detected.
Low-grade astrocytoma generally shows no significant diffusion restriction. ADC values are normal or elevated (typically >1.2 x10⁻³ mm²/s). This finding reflects low cellularity — tumor cells infiltrate normal parenchyma at wide intervals and water molecule movement is not restricted. ADC values are inversely proportional to tumor grade: low grade = high ADC, high grade = low ADC. Decreasing ADC on serial follow-up may be an early indicator of transformation to higher grade — may develop before enhancement increase. Minimum ADC (ADCmin) map is more valuable than mean ADC for evaluating tumor heterogeneity.
Report Sentence
On DWI, no significant diffusion restriction is observed in the lesion, with normal/elevated ADC values (~___ x10⁻³ mm²/s) — consistent with low cellularity.
On perfusion MRI, low rCBV values (<1.75) are observed in low-grade astrocytoma. This finding indicates that neoangiogenesis has not yet developed and is the most reliable perfusion parameter for differentiation from high-grade gliomas (rCBV >1.75). An rCBV threshold of 1.75 can distinguish low- and high-grade gliomas with >90% sensitivity and specificity. rCBV increase on serial follow-up is an early indicator of transformation to higher grade — may develop 6-12 months before enhancement increase. Perfusion MRI is also valuable for biopsy guidance in surgical planning, targeting the most aggressive area (highest rCBV).
Report Sentence
On perfusion MRI, low rCBV values are observed in the lesion (rCBV: ___), without significant neoangiogenesis — consistent with low-grade glial tumor.
MR spectroscopy demonstrates characteristic metabolite patterns for low-grade astrocytoma. The most specific finding is the 2-hydroxyglutarate (2-HG) peak at 2.25 ppm for IDH-mutant tumors — a non-invasive indicator of IDH mutation. Myoinositol (mI) elevation is characteristic of low-grade gliomas (glial cell marker). Choline is mildly elevated (low proliferation rate). NAA is reduced (neuronal damage) but not as dramatic as in GBM. Cho/NAA ratio is usually <2.0 (>2.0 in GBM). Lipid-lactate peak is generally absent (no necrosis). Cho/mI ratio is used in tumor grading — low ratio favors low grade.
Report Sentence
MR spectroscopy demonstrates elevated myoinositol, mildly elevated choline, reduced NAA, and a 2-HG peak at 2.25 ppm in the lesion, consistent with IDH-mutant low-grade glial neoplasm.
On SWI sequences, intratumoral susceptibility signal (ITSS) is generally absent or very minimal in low-grade astrocytoma. This finding reflects the absence of microhemorrhage and neovascular structures. Since ITSS degree is directly proportional to tumor grade, absence of ITSS favors low grade. Increase in ITSS on serial follow-up may be an early indicator suggesting transformation to higher grade. SWI also provides information for surgical planning by evaluating normal venous structures around the tumor.
Report Sentence
On SWI sequences, no significant intratumoral susceptibility signal is detected in the lesion, without findings favoring microhemorrhage or neovascular structures.
Criteria
IDH1/2 mutation positive, ATRX loss, and 1p/19q codeletion negative. Diagnostic triad per WHO 2021 classification. TP53 mutation frequently accompanies.
Distinct Features
No/minimal enhancement, homogeneous T2 hyperintense, low rCBV, 2-HG positive on MRS. Frontal lobe predilection. Absence of 1p/19q codeletion is critical for differentiation from oligodendroglioma.
Criteria
Form of IDH-mutant astrocytoma showing increased mitotic activity. Increased proliferation without CDKN2A/B homozygous deletion.
Distinct Features
Patchy or focal enhancement begins, rCBV starts to increase (1.5-2.5), ADC values begin to decrease, choline elevation becomes more prominent. 2-HG still positive on MRS (IDH-mutant).
Criteria
Highest grade form of IDH-mutant astrocytoma. Presence of microvascular proliferation and/or necrosis OR CDKN2A/B homozygous deletion. Classified separately from IDH-wildtype GBM per WHO 2021 (better prognosis).
Distinct Features
Ring enhancement and necrosis similar to GBM but IDH-mutant status provides better prognosis. 2-HG positive on MRS (evidence of IDH-mutant). rCBV elevated but not as high as IDH-wildtype GBM. Median survival 3-5 years (14-16 months in IDH-wildtype GBM).
Distinguishing Feature
Oligodendroglioma: prominent cortical location, calcification common (70-90%), heterogeneous T2 signal, patchy enhancement more likely, 1p/19q codeletion positive. Low-grade astrocytoma: calcification rare, homogeneous T2 hyperintense, no enhancement, 1p/19q codeletion negative, ATRX loss.
Distinguishing Feature
GBM: marked ring enhancement, central necrosis, elevated rCBV (>1.75), low ADC, lipid-lactate peak, rapid growth, usually >50 years. Low-grade astrocytoma: no enhancement, no necrosis, low rCBV (<1.75), high ADC, elevated myoinositol, slow growth, usually 20-40 years.
Distinguishing Feature
Acute infarct: sudden-onset neurological deficit, vascular distribution (arterial territory), marked restricted diffusion (DWI bright, ADC very low), enhancement may develop over time. Low-grade astrocytoma: slow course, does not follow vascular distribution, no diffusion restriction, no enhancement.
Distinguishing Feature
Gliomatosis cerebri: diffuse infiltrative T2/FLAIR hyperintensity involving at least 3 lobes, minimal mass effect, relative preservation of brain structures. Low-grade astrocytoma: usually single lobe, more focal mass effect, more defined margins (still ill-defined).
Urgency
routineManagement
Tedavi stratejisi cerrahi rezektabilite, tümör lokasyonu, moleküler profil ve hastanın klinik durumuna göre belirlenir. Cerrahi: maksimal güvenli rezeksiyon (awake kraniyotomi ile fonksiyonel alanlar korunarak). Yüksek risk (>40 yaş, subtotal rezeksiyon, progresif semptom): erken adjuvan tedavi (RT + PCV veya temozolomid). Düşük risk (genç, gross total rezeksiyon): aktif izleme tercih edilebilir.Biopsy
NeededFollow-up
İlk yıl her 3-6 ayda, ardından yıllık kontrastlı MRG + perfüzyon + MRS. Yeni kontrast tutulumu, rCBV artışı veya ADC düşüşü malign transformasyon şüphesi ile rebiyopsi/tedavi başlatılmasını gerektirir. RANO-LGG kriterleri tedavi yanıtı değerlendirmesinde kullanılır.Although slow-growing, low-grade astrocytoma carries a risk of transformation to higher grade over time. Molecular profiling (IDH, 1p/19q, ATRX, CDKN2A/B) is mandatory for treatment planning and prognosis determination. IDH-mutant astrocytomas have significantly better prognosis compared to IDH-wildtype tumors. Advanced MRI techniques (perfusion, MRS, DWI) are critical for non-invasive grading, transformation monitoring, and biopsy guidance. Detection of CDKN2A/B homozygous deletion is a grade 4 classification criterion and prognostically determinative.
Low-grade astrocytomas are slow-growing tumors with risk of transformation to higher grade. IDH mutant tumors have better prognosis. Treatment includes surgery, radiotherapy, and chemotherapy (temozolomide/PCV). On follow-up, new enhancement, increased rCBV, or size increase suggests grade progression.